חזרה לתוצאות החיפוש

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1

מצבים רפואיים

Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Waldenstrom Macroglobulinemia (WM) · Mantle Cell Lymphoma (MCL) · Marginal Zone Lymphoma (MZL) · Follicular Lymphoma (FL) · Diffuse Large B-cell Lymphoma (DLBCL) · Primary Central Nervous System Lymphoma (PCNSL)

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • City of Hope, Duarte, California, United States

  • University of California Irvine, Orange, California, United States

  • University of California San Francisco Medical Center, San Francisco, California, United States

  • Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver, Colorado, United States

  • Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

  • Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida, United States

  • The University of Chicago Medical Center, Chicago, Illinois, United States

  • National Institutes of Health Clinical Center, Bethesda, Maryland, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

  • University of Cincinnati Medical Center, Cincinnati, Ohio, United States

  • OSU Wexner Medical Center, Columbus, Ohio, United States

  • Tennessee Oncology, Nashville, Tennessee, United States

  • Baylor University Medical Center, Dallas, Texas, United States

  • MD Anderson Cancer Center, Houston, Texas, United States

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

  • Swedish Cancer Institute, Seattle, Washington, United States

מובילי המחקר

  • Study Director

    Nurix Therapeutics, Inc.

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)